首页> 外文期刊>Cancer genomics & proteomics >Apoptotic regulators: P53 and survivin expression in non-small cell lung cancer.
【24h】

Apoptotic regulators: P53 and survivin expression in non-small cell lung cancer.

机译:凋亡调节剂:非小细胞肺癌中P53和survivin的表达。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Survivin and p53 are proteins that take part in cell cycle and apoptosis regulation. The biological function of survivin is essential for its oncogenic potential. The p53 protein is known to be a guardian of the genome and alterations in its structure enhance resistance to apoptosis. The aim of this study was to detect survivin and p53 expression in 74 non-small cell lung cancer in relation to basic clinicopathological data including the two-year prognosis. PATIENTS AND METHODS: A total of 74 patients with non-small cell lung cancer were recruited into the study. Marker presence was revealed using immunohistochemical methods on paraffin-embedded tissue. RESULTS: The presence of p53 was visible in 52.7% of cases and its expression did not correlate with clinicopathological data. Survivin immunoreactivity was detected in 52.7% of all study cases and was statistically more often found in lung adenocarcinomas than in squamous cell subtype of lung cancer (67% and 37% respectively, p=0.03). Larger tumours, cancer with lymph node metastases and more advanced tumours according to TNM status showed higher incidence of survivin expression, but differences did not reach statistical significance. The survivin immunoreactivity did not correlate with the two-year survival. CONCLUSION: P53 protein expression did not appear to be a clinically important tumour marker. The clearly visible trend to more frequent survivin presence in more advanced non-small cell lung tumours needs further evaluation. The statistically significant difference in survivin immunoreactivity between two major pathological types of non-small cell lung cancer may be important for better selection of patients for specific biological therapy based on apoptosis regulation.
机译:背景:Survivin和p53是参与细胞周期和细胞凋亡调控的蛋白质。 survivin的生物学功能对其致癌潜力至关重要。已知p53蛋白是基因组的守护者,其结构的改变增强了对细胞凋亡的抵抗力。本研究的目的是检测74例非小细胞肺癌中survivin和p53的表达,并与包括两年预后在内的基本临床病理数据相关。患者与方法:总共招募了74例非小细胞肺癌患者。使用免疫组织化学方法在石蜡包埋的组织上发现了标记物的存在。结果:在52.7%的病例中可见p53的存在,其表达与临床病理数据无关。在所有研究病例中检测到Survivin免疫反应性的比率为52.7%,在肺腺癌中比在肺癌的鳞状细胞亚型中更常见(分别为67%和37%,p = 0.03)。根据TNM状况,更大的肿瘤,具有淋巴结转移的癌症和更晚期的肿瘤显示出survivin表达的发生率更高,但差异未达到统计学意义。 survivin免疫反应性与两年生存期无关。结论:P53蛋白表达似乎不是临床上重要的肿瘤标志物。在更晚期的非小细胞肺癌中,更常见的生存素存在的明显趋势需要进一步评估。非小细胞肺癌的两种主要病理类型之间survivin免疫反应性的统计学显着差异可能对更好地选择基于凋亡调控的特定生物疗法的患者很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号